Emmanuel Raffoux

Paris, 75010, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 184 publications

Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.

Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.

Journal: Science translational medicine
Published: July 08, 2026

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Journal: Leukemia
Published: April 14, 2026

Persistent BCR::ABL1-positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome-positive ALL.

Persistent BCR::ABL1-positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome-positive ALL.

Journal: HemaSphere
Published: March 11, 2026

Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort.

Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort.

Journal: Blood cancer journal
Published: March 11, 2026

CEBP and ZEB2 alterations define three distinct subtypes of B-cell acute lymphoblastic leukemia.

CEBP and ZEB2 alterations define three distinct subtypes of B-cell acute lymphoblastic leukemia.

Journal: HemaSphere
Published: February 01, 2026

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Journal: Blood
Published: January 20, 2026

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Journal: Blood
Published: January 20, 2026

Perioperative management and outcome of patients with hematological malignancy.

Perioperative management and outcome of patients with hematological malignancy.

Journal: Anaesthesia, critical care & pain medicine
Published: December 05, 2025

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.

Journal: Leukemia
Published: August 25, 2025

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.

Journal: Leukemia
Published: August 25, 2025

The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer care.

The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer care.

Journal: Annales pharmaceutiques francaises
Published: August 04, 2025

Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors.

Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors.

Journal: HemaSphere
Published: July 25, 2025
Showing 1-12 of 184

Last Updated: 09/26/2026